Comparing the current results to its competitors, Genedx Holdings reported Revenue increase in the 1 quarter 2026 by 18.2 % year on year. The sales growth was above Genedx Holdings 's competitors' average revenue growth of 17.71 %, achieved in the same quarter.
Genedx Holdings 's Comment on Competition and Industry Peers
The company operates in the molecular genetic testing and consulting services sector, competing with specialty and reference laboratories that offer traditional single- and multi-gene tests. The market also includes new entrants such as informatics and analysis pipeline developers, as well as integrated providers of genetic tools and services for health and wellness. Illumina, Inc. is identified as both a competitor and a supplier. Principal competitors include Baylor Genetics, Tempus (through Ambry Genetics), Variantyx, and Rady Children’s Hospital, alongside other commercial and academic laboratories. The company emphasizes reducing costs and enhancing the quality and speed of exome and genome testing to sustain its competitive position.
Overall company sales advanced by 18.2 % Genedx Holdings outperformed its competitors in this segment and improved market share, to approx. 4.2 %. << More on WGS Market Share.
*Market share is calculated based on total revenue.
August 2, 2025
Understanding the Recent Developments at GeneDx Holdings Corp: A Closer Look at Potential Securities Claims and Financial PerformanceGeneDx Holdings Corp. (NASDAQ: WGS), a company known for its commitment to innovative solutions in genomic testing, has been thrust into the spotlight due to a recent press release from Rosen Law Firm. The release indicates ongoing investigations into potential securities claims related to allegations of misleading business information communicated to investors. Despite these challenges, GeneDx Holdings has demonstrated impressive financial performance, particularly in the second quarter of 2025, indicating a complex yet intriguing narrative that warrants further exploration. ...
November 19, 2024
In a significant leap forward in the realm of personalized medicine, GeneDx, a leader in genomic health solutions, has launched GeneDx Discover, an innovative data visualization tool designed to enhance drug development for rare diseases. This pioneering initiative comes amid the company’s robust growth in the genetic testing sector and represents a transformational shift in how biopharmaceutical companies access and utilize genomic data. The Launch of GeneDx Discover On a recent announcement, GeneDx highlighted the capabilities of GeneDx Discover, which allows biopharmaceutical firms access to deidentified and aggregated genetic data derived from GeneDx’s extensive database. This tool aims to empower dr...
November 5, 2024
GeneDx: Riding the Waves of Innovation Amid Market Uncertainty In the rapidly evolving field of genomic medicine, GeneDx (Nasdaq: WGS) stands out as a leader, particularly with its significant contributions to the American Society of Human Genetics (ASHG) annual meeting. Scheduled for early October 2024, the conference is expected to showcase GeneDx s cutting-edge research findings, reinforcing its position in the industry. With a diverse dataset of over 700,000 clinical exomes and genomes, GeneDx has built a foundation of insights that promises to enhance health outcomes across a range of genetic conditions.GeneDx will present its findings through six platform presentations and five posters, demonstrating i...
October 8, 2024
Revolutionizing Healthcare: GeneDx Unveils Insights from Unprecedented Genomic Newborn Screening Initiative In an era where genetic technology is rapidly transforming healthcare landscapes, GeneDx, a prominent entity in the realm of genomic sciences, has announced a monumental milestone in the burgeoning field of newborn screening. The company, listed on Nasdaq under the ticker WGS, has achieved a pioneering feat by providing genomic newborn screenings (gNBS) for an astounding 14,000 infants. This accomplishment underscores GeneDx s commitment to enhancing health outcomes through the insightful application of genomic data.The significance of this achievement is heightened by its context within groundbreaking...
June 10, 2024
GeneDx Partners with Epic Aura to Enhance Rapid Whole Genome Sequencing Services for Pediatric and Neonatal PatientsGeneDx, a leading provider of genetic testing services, has announced a collaboration with Epic Aura to expand access to rapid Whole Genome Sequencing (rWGS) services for pediatric and neonatal patients. This partnership aims to streamline access for health systems and improve the provider and patient journeys by utilizing Epic for electronic connections.By joining forces with Epic Aura, GeneDx looks to increase its commercial footprint and focus on accelerating the utilization of rWGS services in neonatal intensive care units (NICUs). This strategic alliance will enable health systems to lever...
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Pacific Biosciences Of California Inc Share Performance
-14.56%
This Quarter
Pacific Biosciences Of California Inc
Profile
Pacific Biosciences of California Inc's business model revolves around the development and commercialization of innovative sequencing systems that enable scientists and researchers to study the complexity of biology. They provide high-resolution genetic analysis solutions, offering a comprehensive platform that includes consumables, systems, and data analysis software to support genomic analysis.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Sources:
Genedx Holdings Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Genedx Holdings Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
